- Trials with a EudraCT protocol (43)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (2)
43 result(s) found for: Surgical planning.
Displaying page 1 of 3.
EudraCT Number: 2011-001290-78 | Sponsor Protocol Number: 007697 | Start Date*: 2012-01-17 |
Sponsor Name:Barts Health NHS Trust | ||
Full Title: Diagnostic accuracy of MRI, diffusion-weighted MRI, FDG-PET/CT and Fluoro-ethyl-choline PET/CT in the detection of lymph node metastases in surgically staged endometrial and cervical carcinoma | ||
Medical condition: Endometrial and Cervical Cancer | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2010-023888-17 | Sponsor Protocol Number: OMS103-MEN-003 | Start Date*: 2011-05-11 | |||||||||||
Sponsor Name:Omeros Corporation | |||||||||||||
Full Title: A Randomized, Double-Blind, Parallel Group, Vehicle-Controlled Study to Evaluate the Safety and Efficacy of OMS103HP-S Administered in Joint Irrigation Solution to Subjects Undergoing Arthroscopic ... | |||||||||||||
Medical condition: Arthroscopic surgery | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-002936-27 | Sponsor Protocol Number: IOR 157 01 | Start Date*: 2007-12-03 | |||||||||||
Sponsor Name:ISTITUTO ONCOLOGICO ROMAGNOLO | |||||||||||||
Full Title: A Phase II Dose-Finding Study of weekly pemetrexed in combination with Radiotherapy in locally advanced pancreatic adenocarcinoma | |||||||||||||
Medical condition: locally advanced adenocarcinoma of the exocrine pancreas not amenable to surgical resection. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-002729-31 | Sponsor Protocol Number: PETCOLINA1-FINBA | Start Date*: 2020-03-02 | |||||||||||
Sponsor Name:Fundación para la Investigación y la Innovación Biosanitaria del Principado de Asturias (FINBA) | |||||||||||||
Full Title: 18F-fluorocholine PET/CT in primary hyperparathyroidism with negative preoperative localization | |||||||||||||
Medical condition: Primary hyperthyroidism | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-002839-66 | Sponsor Protocol Number: IMVT-1401-3203 | Start Date*: 2023-09-07 | |||||||||||
Sponsor Name:Immunovant Sciences, GmbH | |||||||||||||
Full Title: An Open-label Extension Study for Participants who Completed Study IMVT-1401-3201 or Study IMVT-1401-3202 to Assess the Efficacy and Safety of Batoclimab for the Treatment of Thyroid Eye Disease (TED) | |||||||||||||
Medical condition: Thyroid Eye Disease (TED) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Not Authorised) LV (Trial now transitioned) BE (Trial now transitioned) HU (Trial now transitioned) SK (Trial now transitioned) IT (Trial now transitioned) ES (Ongoing) PL (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-004319-29 | Sponsor Protocol Number: 20120283 | Start Date*: 2013-05-03 | |||||||||||
Sponsor Name:Amgen Inc. | |||||||||||||
Full Title: A Randomized, Double-Blind, Phase 3 Study Evaluating the Efficacy and Safety of ABP 980 Compared with Trastuzumab in Subjects with HER2 Positive Early Breast Cancer | |||||||||||||
Medical condition: HER2 Positive Early Breast Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: GB (Completed) DE (Completed) HU (Completed) SK (Completed) IT (Completed) CZ (Completed) ES (Completed) GR (Completed) BG (Completed) PL (Completed) RO (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-002419-27 | Sponsor Protocol Number: FORMA-02 | Start Date*: 2014-06-11 | ||||||||||||||||
Sponsor Name:Octapharma AG | ||||||||||||||||||
Full Title: Prospective, open-label, uncontrolled, Phase III study to assess the efficacy and safety of Octafibrin for on-demand treatment of acute bleeding and to prevent bleeding during and after surgery in ... | ||||||||||||||||||
Medical condition: Congenital fibrinogen deficiency. | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (Completed) BG (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2015-004306-42 | Sponsor Protocol Number: 2016-1 | Start Date*: 2016-01-27 | |||||||||||
Sponsor Name:Stomatološka klinika UKC, Ljubljana | |||||||||||||
Full Title: Comparison of the efficacy of treatment of chronic periodontitis with scaling and root-planning alone or in combination with azithromycin - a prospective, double blind, randomised clinical trial | |||||||||||||
Medical condition: Number of remaining deep pockets after treatment of patients with chornic periodontitis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: SI (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2022-002787-68 | Sponsor Protocol Number: IMVT-1401-3201 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Immunovant Sciences, GmbH | |||||||||||||
Full Title: A Phase 3, Multi-center, Randomized, Quadruple-masked, Placebo-controlled Study of Batoclimab for the Treatment of Participants with Active Thyroid Eye Disease (TED) | |||||||||||||
Medical condition: Thyroid Eye Disease (TED) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Trial now transitioned) IT (Trial now transitioned) PL (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-004236-19 | Sponsor Protocol Number: PUB2014 | Start Date*: 2015-02-13 | |||||||||||
Sponsor Name:Landstinget i Östergötland | |||||||||||||
Full Title: Pudendal block after posterior vaginal surgery. A randomized controlled trial on postoperative pain. | |||||||||||||
Medical condition: postoperative pain | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: SE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-002713-58 | Sponsor Protocol Number: HZNP-TEP-302 | Start Date*: 2018-08-13 | |||||||||||
Sponsor Name:Horizon Therapeutics USA, Inc. | |||||||||||||
Full Title: Multicenter, Safety and Efficacy, Open-Label Extension Study Evaluating Teprotumumab (HZN.001) Treatment in Subjects with Thyroid Eye Disease | |||||||||||||
Medical condition: Thyroid Eye Disease (TED) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2022-002788-30 | Sponsor Protocol Number: IMVT-1401-3202 | Start Date*: 2023-07-13 | |||||||||||
Sponsor Name:Immunovant Sciences, GmbH | |||||||||||||
Full Title: A Phase 3, Multi-center, Randomized, Quadruple-masked, Placebo-controlled Study of Batoclimab for the Treatment of Participants with Active Thyroid Eye Disease (TED) | |||||||||||||
Medical condition: Thyroid Eye Disease (TED) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Trial now transitioned) BE (Trial now transitioned) LV (Trial now transitioned) HU (Trial now transitioned) SK (Trial now transitioned) ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-002784-10 | Sponsor Protocol Number: CESM | Start Date*: 2012-07-12 | |||||||||||
Sponsor Name:AZIENDA OSPEDALIERA ARCISPEDALE S. MARIA NUOVA | |||||||||||||
Full Title: Clinical trial comparing contrast enhanced spectral digital mammography (CESM) and magnetic resonance imaging (MRI) to evaluate the effectiveness of neoadjuvant chemotherapy in patients with locall... | |||||||||||||
Medical condition: patient with cito-istologic diagnosis of locally advanced breast cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-001622-29 | Sponsor Protocol Number: ALI-P01-21-006 | Start Date*: 2023-03-01 | |||||||||||
Sponsor Name:Alimera Sciences Europe Limited | |||||||||||||
Full Title: A NON-RANDOMISED, OPEN-LABEL, UNCONTROLLED, MULTI-CENTRE, PHASE IIIB STUDY EVALUATING THE SAFETY AND EFFICACY OF FLUOCINOLONE ACETONIDE 190 MICROGRAMS INTRAVITREAL IMPLANT IN PAEDIATRIC SUBJECTS FR... | |||||||||||||
Medical condition: Non-Infectious Uveitis affecting the posterior segment | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) DE (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-001098-16 | Sponsor Protocol Number: MO10/9353 | Start Date*: 2011-06-06 |
Sponsor Name:University of Leeds | ||
Full Title: STAR: A Randomised Multi-Stage Phase II/III trial of Sunitinib comparing Temporary cessation with Allowing continuation, at the time of maximal radiological response, in the first-line treatment of... | ||
Medical condition: Metastatic and/or locally advanced Renal Clear Cell Carcinoma | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (GB - no longer in EU/EEA) | ||
Trial results: (No results available) |
EudraCT Number: 2017-000653-39 | Sponsor Protocol Number: IMR-SCD-102 | Start Date*: 2017-10-19 | |||||||||||
Sponsor Name:Imara, Inc | |||||||||||||
Full Title: A Phase 2a, Randomised, Double-Blind, Placebo-Controlled Study of IMR-687 in Adult Patients with Sickle Cell Anaemia (Homozygous HbSS or Sickle-β0 Thalassemia) | |||||||||||||
Medical condition: Sickle cell disease (SCD) is a rare inherited red blood cell (RBC) disorder characterized by chronic hemolysis, debilitating pain, progressive multiorgan damage, and premature death. SCD is caused ... | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-005115-16 | Sponsor Protocol Number: FORMA-04 | Start Date*: 2020-04-22 |
Sponsor Name:Octapharma AG | ||
Full Title: Prospective, open-label, uncontrolled, Phase III study to assess the efficacy, safety, and pharmacokinetics of Octafibrin for on-demand treatment of acute bleeding and to prevent bleeding during an... | ||
Medical condition: Congenital fibrinogendeficiency | ||
Disease: | ||
Population Age: Newborns, Infants and toddlers, Children, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2019-001748-23 | Sponsor Protocol Number: SGM-LARRC | Start Date*: 2019-08-07 | ||||||||||||||||
Sponsor Name:Leiden University Medical Center | ||||||||||||||||||
Full Title: Multicenter, open-label, controlled, parallel arms clinical study on the performance of SGM-101, a fluorochrome-labeled anti-carcino-embryonic antigen (CEA) monoclonal antibody, for locally advance... | ||||||||||||||||||
Medical condition: Locally advanced rectal cancer Recurrent rectal cancer | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: NL (Trial now transitioned) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-004167-45 | Sponsor Protocol Number: 1305-0013 | Start Date*: 2020-05-18 | |||||||||||
Sponsor Name:Boehringer Ingelheim Finland Ky | |||||||||||||
Full Title: A randomised, double-blind, placebo-controlled parallel group study in IPF patients over 12 weeks evaluating efficacy, safety and tolerability of BI 1015550 taken orally. | |||||||||||||
Medical condition: Idiopathic Pulmonary Fibrosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FI (Completed) NL (Completed) DK (Completed) CZ (Completed) DE (Completed) HU (Completed) GB (GB - no longer in EU/EEA) AT (Completed) PL (Completed) SK (Prematurely Ended) GR (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-000377-12 | Sponsor Protocol Number: CHUBX2014/26 | Start Date*: 2017-09-18 | ||||||||||||||||
Sponsor Name:CHU de Bordeaux | ||||||||||||||||||
Full Title: MISOBOLD - Prostate cancer hypoxia using BOLD MRI and 18F-FMISO PET imaging | ||||||||||||||||||
Medical condition: Prostate cancer | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: FR (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
